Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

20,689 21,632

Deferred revenue 57,027 61,349

Deferred gain 7,323 8,680

Other long-term liabilities 11,159 5,911

Total liabilities 459,720 510,664

Commitments and contingencies

Stockholders' equity:

Preferred stock - -

Common stock 9 9

Capital in excess of par value 1,309,973 1,302,541

Accumulated other comprehensive income (478) 1,643

Accumulated deficit (1,200,872) (1,089,754)

Total stockholders' equity 108,632 214,439

Total liabilities and stockholders' equity $568,352 $725,103

(1) The consolidated balance sheet at December 31, 2007 has been derived

from the audited financial statements at that date but does not

include all of the information and notes required by generally

accepted accounting principles in the United States for complete

financial statements. Certain 2007 amounts have been reclassified

between line items to conform with the 2008 presentation.

NEKTAR THERAPEUTICS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, except per share information)

(unaudited)

Nine Months Ended

September 30,

2008 2007

Cash flows used in operating activities:

Net loss $(1
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... HealthDay Reporter , , FRIDAY, May 24 (HealthDay News) -- ... But it was a physical challenge in her childhood ... sport. "I was an 11-year-old girl with my ... diagnosed by my orthopedic surgeon," said Lewis, who has ... and the American Academy of Orthopaedic Surgeons so she ...
(Date:5/24/2013)... Pomona, Calif. (PRWEB) May 24, 2013 ... has retained its status of “Full Accreditation” for the ... (AVMA) Council on Education (COE). , “This is a ... of our hard work and student outcomes,” said College ... want to express my appreciation to the faculty, staff, ...
(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
Breaking Medicine News(10 mins):Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2
... found that the United States, which has the most expensive ... rich countries for quality, access and efficiency of healthcare. ... performance, to other countries and differs most notably in the ... to the studies. ,Says Commonwealth Fund president ...
... experts in India are questioning the efficacy of the ... the country. The increasing number of TB cases ... with how the DOTS strategy has been implemented, according ... has implemented various TB control programs that are used ...
... on Tuesday said that Thailand will not issue compulsory ... if pharmaceutical companies offer prices lower than those charged ... came one day after Abbott Laboratories and Thailand failed ... antiretroviral drugs Aluvia and Kaletra. ,The Thai ...
... in doctors reflects the reality in the NHS. It is ... doctors to improve the quality and experience of care for ... service. ,In virtually all of the questions patients ... answered that doctors are providing high standards of care. ...
... most common but contentious accommodation requests made by students ... entrance and licensing exams. According to a new study ... time respond to exams similarly to average students under ... there is no real evidence to suggest that the ...
... East Anglia in Norwich and Kings College in London, has ... used to find out not only the kind of drugs ... diseases. ,Lead researcher, David A. Russell, and his ... about the lifestyle of the person whose fingerprints have been ...
Cached Medicine News:Health News:Americans Get Least Value For Money In Healthcare 2Health News:Thailand Will Not Issue Compulsory Licenses for Patented Drugs 2Health News:Now Fingerprints can Be Used to Detect Drugs and Diseases Instead of Blood Samples 2
(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer").  On 20 May ...
(Date:5/24/2013)... CITY, England and BOSTON ... leading GPCR drug discovery and development company, is pleased to announce ... as a Consultant to augment the Company,s business development capabilities in ... Mr Usui has more than 15 years of experience in business ... roles at Perlegen Sciences, Inc., Roche Pharma ( Japan ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 ... un destacado desarrollador y fabricante de herramientas de ... diagnosis y tratamiento de la enfermedad vascular periférica ... ensayo ADVISE ( Ad enosine V asodilator ... valuation) II durante la sesión de ensayo clínico ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Biosciences, Inc. (Nasdaq: NBIX ) announced today that ... preclinical work was presented at the 91st Annual Meeting of ... 2009. , , The first clinical abstract presentation at ... in which elagolix was evaluated over six weeks (42 days) ...
... --Orally Active Enhancer of Human Nerve Growth Factor Has ... Applications Include Neuropathies, Alzheimer,s and Huntington,s Disease and Others-- ... CeNeRx BioPharma, Inc., a clinical stage company developing ... nervous system (CNS), today announced that it has obtained ...
Cached Medicine Technology:Neurocrine Biosciences Presents Elagolix Data 2Neurocrine Biosciences Presents Elagolix Data 3Neurocrine Biosciences Presents Elagolix Data 4CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 2CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 3
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
... Marco Radiusgauges are available with either a ... in either monocular or binocular form. All ... one, measuring both the curvature and thickness ... The accuracy of both measurements is increased ...
... or for those seeking high quality ... is an economical, full-function instrument-delivery system. ... body offer rugged, maintenance-free service. And ... two arms provided as standard equipment--adjusts ...
... Marco could offer you a choice of two ... Chart Projector uses a halogen bulb for longer ... use. The Marco Chart Projector offers a lower ... includes a thermistor for extended bulb life. And ...
Medicine Products: